(Q30323499)

18 June 2017

1 reference

title

Beta-adrenergic blocker mortality trials in congestive heart failure. (English)

1 reference

18 June 2017

1 reference

congestive heart failure

1 reference

Teerlink JR

1

1 reference

PubMed ID

10568667

18 June 2017

Massie BM

series ordinal

2

1 reference

PubMed ID

10568667

18 June 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

American Journal of Cardiology

18 June 2017

1 reference

18 June 2017

84

1 reference

18 June 2017

9A

1 reference

18 June 2017

94R-102R

1 reference

Beta-blocker treatment for chronic heart failure. The frog prince

18 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

The sympathetic nervous system in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Appreciating alpha-adrenergic receptors and their role in ischemic left ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Beneficial effects of long-term beta-blockade in congestive cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Haemodynamic effects of acute beta-adrenergic receptor blockade in congestive cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

An overview of contemporary etiologies of congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Carvedilol and the Food and Drug Administration approval process: an introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

End-point interpretation in clinical trials: the case for discipline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

The evidence for beta blockers in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900709-2

10.1016/S0002-9149(99)00709-2

7 January 2021

Identifiers

DOI

1 reference

18 June 2017

1 reference

PubMed ID

10568667